Press release 📈 Stocks 🌍 Sweden

Enorama Pharma Calls EGM for 4 December to Decide on Future Operations

Enorama Pharma shareholders will vote on 4 December 2026 on continuing operations after the board confirmed equity is fully restored, supported by a new USD 2,500,000 loan and a debt-for-equity swap at 0.4 SEK per share with DS Global.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: ENOR → 5/10 (55% confidence).

📊 Affected Assets (1)

ENOR
Neutral 🤖 55%
📅 Short-term 🌍 SE · Explicit

The board proposes that the EGM on 4 December 2026 continue operations instead of liquidation, and the control balance sheet shows equity fully restored - positive for survival. However, the 13 November 2026 supplemental agreement converts outstanding loans (including the new USD 2,500,000 facility) into shares at 0.4 SEK per share, and DS Global could exceed 30% ownership, meaning substantial dilution at a fixed low price. The positive continuation signal and the dilution largely offset each other.

Catalysts
  • • Extra general meeting on 4 December 2026 decides on continuing operations versus liquidation
  • • Decision on introducing 9% annual interest in the USD 2,500,000 loan agreement with DS Global
Risk Factors
  • • Major dilution from offset issuance at 0.4 SEK per share
  • • DS Global (holding ~29.81%) could exceed 30% ownership via the conversion

🎯 Key Takeaways

  • The EGM is scheduled for 4 December 2026 to vote on continuing operations versus liquidation.
  • A new USD 2,500,000 loan agreement with DS Global includes a proposed 9% annual interest rate.
  • Outstanding loans will be repaid via a directed offset issue at 0.4 SEK per share, potentially pushing DS Global's ownership above 30%.
  • The company's equity is reported as fully restored to 24,006,297 SEK following the new loan and supplemental agreement.

📝 Executive Summary

Enorama Pharma AB has convened an extraordinary general meeting for 4 December 2026 to determine whether to continue operations or enter liquidation. The board proposes continuing operations, noting that the company's equity is fully restored following a new USD 2,500,000 loan agreement and a debt-to-equity conversion plan with DS Global.

❓ FAQ

Will Enorama Pharma be liquidated?

The board proposes that the company continue operations, and the control balance sheet shows that equity is fully restored. The extra general meeting on 4 December 2026 will make the final decision, but shareholders representing more than half of the votes cast must approve any decision.

What does the new loan from DS Global mean for shareholders?

The USD 2,500,000 loan runs until 31 December 2027 and, together with prior loans, will be repaid with newly issued shares at 0.4 SEK per share through a directed offset issue. This means dilution, and DS Global could come to hold more than 30% of the shares. Shareholders will also vote on adding a 9% annual interest rate to the new loan.